Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea's Cabinet Passes Regulations Needed For New "Drug-Pricing System"

This article was originally published in PharmAsia News

Executive Summary

SEOUL - In a June 1 Cabinet meeting, the South Korean government approved new regulations that will enable the Ministry for Health, Welfare and Family Affairs to speed up the launch of a new "drug-pricing system" that it hopes will weed out drug rebates

You may also be interested in...

Korea's Anti-Rebate Laws Seen Sparking More Demand For MNC Products

SEOUL - Last week's passage of long-awaited "anti-rebate laws" that enable courts to punish both contributors and receivers of rebates, could trigger more demand from doctors to prescribe branded products from multinational companies, industry watchers said

New Pricing System Could Deal A Blow To South Korea's Generic-Dependent Companies

SEOUL - As part of its effort to root out illegal rebates, the Ministry for Health, Welfare and Family Affairs said it would launch a new "drug-pricing system" in October aimed at compensating hospitals that buy drugs at lower prices than their government-set maximum prices

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts